Cv Rx, Inc. CVRX
We take great care to ensure that the data presented and summarized in this overview for CVRx, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding CVRX
View all-
Johnson & Johnson New Brunswick, NJ4.1MShares$28.6 Million16.67% of portfolio
-
Nea Management Company, LLC Timonium, MD2.03MShares$14.1 Million2.35% of portfolio
-
Parkman Healthcare Partners LLC Stamford, CT1.23MShares$8.58 Million1.95% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.01MShares$7.03 Million0.0% of portfolio
-
Black Rock Inc. New York, NY876KShares$6.11 Million0.0% of portfolio
-
Emerald Advisers, LLC591KShares$4.12 Million0.36% of portfolio
-
Balyasny Asset Management LLC Chicago, IL408KShares$2.85 Million0.01% of portfolio
-
Lord, Abbett & Co. LLC Jersey City, NJ397KShares$2.77 Million0.02% of portfolio
-
Parian Global Management LP Pound Ridge, NY393KShares$2.74 Million11.93% of portfolio
-
Silvercrest Asset Management Group LLC New York, NY370KShares$2.58 Million0.03% of portfolio
Latest Institutional Activity in CVRX
Top Purchases
Top Sells
About CVRX
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Insider Transactions at CVRX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
May 15
2025
|
Kirk G. Nielsen |
BUY
Open market or private purchase
|
Indirect |
10,966
+0.57%
|
$54,830
$5.45 P/Share
|
|
May 14
2025
|
Kirk G. Nielsen |
BUY
Open market or private purchase
|
Indirect |
61,200
+3.12%
|
$306,000
$5.23 P/Share
|
|
May 13
2025
|
Kirk G. Nielsen |
BUY
Open market or private purchase
|
Indirect |
101,413
+5.23%
|
$507,065
$5.29 P/Share
|
|
May 13
2025
|
Mudit K. Jain |
BUY
Open market or private purchase
|
Direct |
150
+2.88%
|
$750
$5.26 P/Share
|
|
May 12
2025
|
Kirk G. Nielsen |
BUY
Open market or private purchase
|
Indirect |
25,200
+1.43%
|
$100,800
$4.79 P/Share
|
|
May 12
2025
|
Mudit K. Jain |
BUY
Open market or private purchase
|
Direct |
1,500
+23.44%
|
$6,000
$4.66 P/Share
|
|
May 12
2025
|
Kevin Hykes PRES & CEO |
BUY
Open market or private purchase
|
Direct |
5,000
+3.62%
|
$20,000
$4.84 P/Share
|
|
Feb 28
2025
|
Paul Verrastro CHIEF MKTG & STRAT OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
16,000
+48.73%
|
-
|
|
Feb 28
2025
|
Philip B. Adamson Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+50.0%
|
-
|
|
Feb 28
2025
|
Jared Oasheim CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
22,000
+37.01%
|
-
|
|
Feb 28
2025
|
Robert Allen John Chief Revenue Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55,000
+50.0%
|
-
|
|
Feb 28
2025
|
Kevin Hykes PRES & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
98,000
+43.36%
|
-
|
|
Nov 21
2024
|
Paul Verrastro CHIEF MKTG & STRAT OFFICER |
SELL
Bona fide gift
|
Direct |
1,040
-55.47%
|
-
|
|
Nov 19
2024
|
Paul Verrastro CHIEF MKTG & STRAT OFFICER |
SELL
Open market or private sale
|
Direct |
1,430
-43.27%
|
$18,590
$13.58 P/Share
|
|
Nov 19
2024
|
Paul Verrastro CHIEF MKTG & STRAT OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+43.07%
|
$12,500
$5.14 P/Share
|
|
Aug 15
2024
|
Joseph P Slattery |
BUY
Open market or private purchase
|
Direct |
3,000
+8.92%
|
$24,000
$8.1 P/Share
|
|
Aug 08
2024
|
Joseph P Slattery |
BUY
Open market or private purchase
|
Direct |
3,000
+9.79%
|
$24,000
$8.24 P/Share
|
|
Aug 06
2024
|
Joseph P Slattery |
BUY
Open market or private purchase
|
Direct |
2,500
+9.21%
|
$22,500
$9.09 P/Share
|
|
Aug 05
2024
|
Kevin Hykes PRES & CEO |
BUY
Open market or private purchase
|
Direct |
30,000
+50.0%
|
$240,000
$8.36 P/Share
|
|
Mar 25
2024
|
Craig E. Palmer SVP, U.S. SALES |
BUY
Exercise of conversion of derivative security
|
Direct |
934
+24.73%
|
$0
$0.24 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 211K shares |
|---|---|
| Exercise of conversion of derivative security | 2.5K shares |
| Open market or private purchase | 244K shares |
| Bona fide gift | 1.04K shares |
|---|---|
| Open market or private sale | 1.43K shares |